| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/BJH.13149 |
| P698 | PubMed publication ID | 25284608 |
| P50 | author | Mitchell Smith | Q47320517 |
| P2093 | author name string | Eric D Hsi | |
| Jeffrey Lin | |||
| Lisa Durkin | |||
| Juraj Bodo | |||
| Xiaoxian Zhao | |||
| Danyu Sun | |||
| P2860 | cites work | Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma | Q24613755 |
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 | ||
| Circumventing Cancer Drug Resistance in the Era of Personalized Medicine | Q34274940 | ||
| Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis | Q36562739 | ||
| Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. | Q38999783 | ||
| Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma | Q42553000 | ||
| B cell receptor-induced cAMP-response element-binding protein activation in B lymphocytes requires novel protein kinase Cdelta | Q44892444 | ||
| Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation | Q44926251 | ||
| Toward New Treatments for Mantle-Cell Lymphoma? | Q46607983 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mantle cell lymphoma | Q268713 |
| ibrutinib | Q5984881 | ||
| P304 | page(s) | 765-768 | |
| P577 | publication date | 2014-10-04 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. | |
| P478 | volume | 168 |
| Q38659428 | B-cell receptor pathway modulators in NHL. |
| Q38896657 | Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma |
| Q42553373 | CCMCL1: a new model of aggressive mantle cell lymphoma |
| Q39325783 | Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies |
| Q37702281 | Development of venetoclax for therapy of lymphoid malignancies. |
| Q38919666 | Distinct and Overlapping Functions of TEC Kinase and BTK in B Cell Receptor Signaling |
| Q93223071 | Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma |
| Q47424531 | Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia |
| Q37404843 | FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. |
| Q46370948 | Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax |
| Q37629080 | Gene mutations and actionable genetic lesions in mantle cell lymphoma. |
| Q38545545 | Ibrutinib in B lymphoid malignancies |
| Q26783430 | Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion |
| Q36544565 | Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells |
| Q37688439 | Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation |
| Q54990441 | Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen. |
| Q101121282 | Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances |
| Q38516704 | Novel agents in mantle cell lymphoma |
| Q39290199 | Novel agents in mantle cell lymphoma |
| Q35958056 | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia |
| Q58567814 | Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma |
| Q53704458 | Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All. |
| Q49888075 | Role of Bruton's tyrosine kinase in B cells and malignancies |
| Q39472422 | Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies |
| Q89866309 | Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia |
| Q38691282 | Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma. |
| Q94671635 | Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies |
| Q38722012 | Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. |
| Q38744922 | Targeting of B-cell receptor signalling in B-cell malignancies. |
| Q47804413 | The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma |
| Q51014811 | The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia |
| Q88766200 | Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report |
| Q38853500 | Venetoclax: First Global Approval |
| Q41070355 | Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. |
| Q39694093 | p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL. |
Search more.